Skip to main content
SpringerLink
Log in

Combined Use of Auto-Grafting and Non-Myeloablative Allografting for the Treatment of Hematologic Malignancies and Metastatic Breast Cancer

  • Chapter
Non-Myeloablative Allogeneic Transplantation

Part of the book series: Cancer Treatment and Research ((CTAR,volume 110))

Abstract

Conventional allografting has relied on a combination of myeloablative and immunosuppressive therapies, which results in substantial morbidity and mortality. To circumvent the problems inherent to the toxicity and treatment related deaths associated with allografting, it has been recently assessed that it is possible to achieve engraftment of donor hematopoietic stem cells (HSC) after immunosuppressive therapy combined or not with myelosuppressive but nonmyeloablative therapy.1-5The basic observation which serves as the rationale for non-myeloablative hematopoietic stem cell transplantation (NST) originates from the documented therapeutic potential of adoptive transfer of alloreactive donor lymphocytes to eradicate resistant malignant host cells escaping maximally tolerated doses of chemoradiotherapy. This is an observation that has provided an option for cure of patients with a large variety of hematologic malignancies,6-8especially chronic myeloid leukemia (CML).7-14

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Giralt S, Estey E, Albitar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531–4536, 1997.

    PubMed  CAS  Google Scholar 

  2. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763, 1998.

    PubMed  CAS  Google Scholar 

  3. Storb R: Nonmyeloablative preparative regimens: experimental data and clinical practice. ASCO: 1999 Educational Book, pp. 241, 55th Annual Meeting, May 15–18, Atlanta, GA.

    Google Scholar 

  4. Carella A.M., Champlin R., Slavin S., et al: Mini-allografts: ongoing trials in humans. Bone Marrow Transplantation 25: 345–350, 2000.

    Article  PubMed  CAS  Google Scholar 

  5. Spitzer T.R.: Nonmyeloablative Allogeneic Stem Cell Transplant Strategies and the Role of Mixed Chimerism. The Oncologist 5:215–223, 2000.

    Article  PubMed  CAS  Google Scholar 

  6. Slavin S, Or R, Naparstek E, et al: Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72;407a, 1988.

    Google Scholar 

  7. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp. Hematol. 23:1553–1562, 1995.

    CAS  Google Scholar 

  8. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195–2204, 1996.

    PubMed  CAS  Google Scholar 

  9. Kolb HJ, Mittermüller J, Clemm C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465, 1990.

    PubMed  CAS  Google Scholar 

  10. Porter DL, Roth MS, McGarigle C, et al: Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engi J Med 330:100–106, 1994.

    Article  CAS  Google Scholar 

  11. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050, 1995.

    PubMed  CAS  Google Scholar 

  12. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261–1268, 1995.

    PubMed  CAS  Google Scholar 

  13. Giralt S, Hester J, Huh Y, et al: CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337–4343, 1995.

    PubMed  CAS  Google Scholar 

  14. Collins RH Jr, Shpilberg O, Drobyski WR, et al: Donor lymphocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433–444, 1997.

    PubMed  Google Scholar 

  15. Childs RW, Clave E, Contentin N., et al: Reduced toxicity and TRM following nonmyeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. Blood 94: 3234–3241, 1999.

    PubMed  CAS  Google Scholar 

  16. Eilb B, Schwaighofer H, Nachbaur D, et al: Evidence for a graft-versustumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501–1508, 1996.

    Google Scholar 

  17. Khouri IF, Keating M, Körbling M, et al: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817–2824, 1998.

    PubMed  CAS  Google Scholar 

  18. Sykes M, Preffer F, Saidman SL, et al: Mixed lympho-hematopoietic chimerism is achievable following non-myeloablative therapy and HLA-mismatched donor marrow transplantation. Lancet 353:1755–1759, 1998.

    Article  Google Scholar 

  19. McSweeney PA, Storb R.: Mixed Chimerism: preclinical studies and clinical applications. Biol. Blood Marrow Transplant 5:192–203, 1999.

    Article  CAS  Google Scholar 

  20. Childs R, Clave E, Contentin N, et al: Reduced toxicity and transplant related mortality (TRM) following non-myeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. Blood 94:3234–3241, 1999.

    PubMed  CAS  Google Scholar 

  21. Sharabi Y, Abraham VS, Sykes M, et al: Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 9:191–197, 1992.

    PubMed  CAS  Google Scholar 

  22. Pelot MR, Pearson DA, Swenson K, et al: Lymphohematopoietic graftvs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol. Blood Marrow Transplant 5:133–135, 1999.

    Article  CAS  Google Scholar 

  23. Spitzer TR, McAfee S, Sackstein R, et al: The intentional induction of mixed chimerism and achievement of anti-tumor responses following non-myeloablative conditioning therapy and HLAmatched donor bone marrow transplantation for refractory hematologic malignancies 2000. Biol Blood Bone Marrow (in press).

    Google Scholar 

  24. Carella AM, Cunningham I, Lerma E, et al: Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J. Clin. Oncol. 15:1575–1582, 1997

    PubMed  CAS  Google Scholar 

  25. Chopra R, McMillan AK, Linch DC. The place of high-dose BEAM therapy and ABMT in poor-prognosis Hodgkin’s disease: a single-center eight-year study of 155 patients. Blood 81:1137–1145, 1993.

    PubMed  CAS  Google Scholar 

  26. Priebe T, Platsoucas CD, Sieki H, et al: Purine nucleoside modulation of function of human lymphocytes. Cell lmmunol. 129:321–326, 1990.

    Article  CAS  Google Scholar 

  27. Seymour JF, Khouri IF, Champlin RE, Keating MJ. Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Am J Clin Oncol. 17:362–367, 1994

    Article  Google Scholar 

  28. Mehta J, Powles R, Singhal S, et al: T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure. Bone Marrow Transplant 17:881–885, 1996

    PubMed  CAS  Google Scholar 

  29. Wijermans PW, Gerrits WB, Haak HL, et al: Severe immunodeficiency in patient treated with fludarabine monophosphate. Eur J Haematol 50:292–296, 1993

    Article  PubMed  CAS  Google Scholar 

  30. Carella AM, Lerma E, Corsetti MT, et al: Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. British Journal of Haematology 103: 565–567, 1998.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Angelo M. Carella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Germana Beltrami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Enrica Lerma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marina Cavaliere
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria T. Corsetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Blood and Marrow Transplantation Division, University of California, San Diego, USA

    Asad Bashey M.D., Ph.D.  & Edward D. Ball M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Carella, A.M., Beltrami, G., Lerma, E., Cavaliere, M., Corsetti, M.T. (2002). Combined Use of Auto-Grafting and Non-Myeloablative Allografting for the Treatment of Hematologic Malignancies and Metastatic Breast Cancer. In: Bashey, A., Ball, E.D. (eds) Non-Myeloablative Allogeneic Transplantation. Cancer Treatment and Research, vol 110. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0919-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0919-6_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5304-1

  • Online ISBN: 978-1-4615-0919-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation